Eisai Co., Ltd. engages in the development, manufacture, and sale of prescription medicines and over-the-counter products. It operates through the Pharmaceutical Products Business and Other Business segments. The Pharmaceutical Products Business segment handles prescription and generic drugs, diagnostics, and consumer healthcare business in Japan, which manages over-the-counter drugs. The Other Business segment deals with food additives and chemicals. The company was founded by Toyoji Naito in November 1936 and is headquartered in Tokyo, Japan.

Sekisui Chemical Co., Ltd. engages in the manufacture of high-performance plastics for medical, automotive, and information technology industries; and residential housing construction. It operates through the following segments: Housing, Environment and Lifeline, High Performance Plastics, Medical, and Others. The Housing segment handles the construction, sale, and renovation of housing units. It also provides real estate and housing services. The Environment and Lifeline segment offers PVC pipes and fittings, pipe rehabilitation materials, reinforced plastic composite pipes, and synthetic wood. The High-Performance Plastics segment sells interlayer films for laminated glass, foamed polyolefin, tapes, fine particles for liquid crystals, photosensitive materials, and functional resins for infrastructure materials. The Medical segment covers clinical diagnostic reagents, clinical testing equipment, active pharmaceutical ingredients and intermediates. The Others segment covers film-type lithium-ion batteries. The company was founded on March 3, 1947 and is headquartered in Osaka, Japan.

Sansho Co., Ltd. is a Japanese private company with a presence in Thailand that engages in research & development, manufactures and distributes of pharmaceutical and cosmetic products.

Navipharm Co. Ltd. is a Vietnamese private company located in Dong Da dist that manufactures pharmaceuticals products.

Withus Pharmaceutical Co., Ltd. manufactures and sells prescription drugs. The company was founded on August 19, 2004 and is headquartered in Seoul, South Korea.

Established in 1945, Amorepacific is Korea’s No.1 beauty company and a blue-chip corporation. Amorepacific owns nearly 30 well-known brands and has been developing rapidly worldwide. Amorepacific pays great attention to product research and development through research centers located in Korea, France, Japan and Shanghai, to develop premium and high quality skincare and cosmetics products. The Group chose Hong Kong as a strategic bridgehead for the expansion of its presence across the Greater China region and the rest of the world. Two flagship brands - LANEIGE and Sulwhasoo, were introduced in Hong Kong in 2002 and 2004 respectively. The eponymous luxury brand – AMOREPACIFIC, was introduced in Hong Kong in 2014. In 2015, ETUDE HOUSE, a playful cosmetics brand, made its debut in the territory. In 2018, the Company set foot in the personal care product market, introducing the Group’s legendary hair care brand ‘Ryo’ into Hong Kong.

Operates as a chronic disease hospital

Sannova Co. Ltd., part of Alfresa Holdings Corp., is a company headquartered in Ota, Japan. The firm engages in research, development, manufacturing, and distribution of pharmaceutical products and skin-care products.

MEDA Pharma is a company that provides healthcare services to people of high quality with safety. A medium-sized pharmaceutical company, Madaus GmbH belongs to the worldwide operating Meda Group. They manufacture pharmaceuticals as well as scientifically based health products such as medical devices, cosmetics, and dietary supplements. Its mission was to set new standards for health care, give 7 billion people access to high-quality medicine, and carry out research to address unmet healthcare needs.

Established in 1973 in Korea, Hanmi Pharmaceuticals now is one of the top 5 pharmaceutical companies in terms of revenue, and the most R&D focused company with the highest R&D investment for several years. Hanmi has been successful for a few decades with high flexibility, continuously changing its market/development strategy from first generics to IMD & FDC (Incrementally Modified Drug and Fixed Dose Combination) to new drug development including innovative small molecules and biologics. During the period of significant changes, Hanmi made multiple strategic collaboration relationships with multinational companies and biotech companies. Based on the success in 1980s and 1990s, Hanmi started its Chinese operation in 1996 with establishment of Beijing Hanmi. Now, Beijing Hanmi grew as a well-localized and well-settled Chinese company with more than 1,300 staffs including R&D, sales / marketing, and manufacturing experts and significant growth rate higher than 20% every year. Currently, Hanmi and Beijing Hanmi is closely collaborating on various business opportunities and new drug development projects as well as sales and marketing in Chinese territories. As the only Asian company with significant presence both in Korea and China, as the most R&D focused company with number of clinical stage projects with competitiveness, and as the company with open innovation based on multiple development/marketing collaborations, Hanmi is trying to develop and provide differentiated treatment options to patients suffering from various disease.

Taisho Pharmaceutical Co., Ltd. engages in the manufacture and sale of pharmaceutical products. It operates through the following divisions: Self-Medication, Prescription Pharmaceutical and Overseas Development. The Self-Medication division deals with the research, development, and production of over-the-counter (OTC) drugs, medical supplies, food for specific health use, and hygiene products. The Prescription Pharmaceutical division handles research and development of new drugs in the fields of central nervous system diseases, metabolic diseases, infectious diseases, and inflammatory diseases. The Overseas Development division markets energy drinks and OTC pharmaceuticals overseas. The company was founded on October 12, 1912 and is headquartered in Tokyo, Japan.

Hunan Yada Pharmaceutical Co., Ltd., established on 1998-12-08, Business range includes tablet,hard capsule,Granules,syrup,oral solution(Contains Chinese herbal extracts)production and sales;Chinese patent medicine production;Chemical raw materials,Manufacture of chemical preparations.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

ENZYCHEM LIFESCIENCES Corp. engages in developing, manufacturing, and distributing pharmaceutical products. Its main products include beta lactam antibiotics, non-beta lactam active pharmaceutical ingredient (APIs), and others. The beta lactam antibiotics include Cefazedone, Cefbuperazone and Ceftizoxime. The non-beta lactam APIs include D-cycloserine and Talniflumate. The company was founded on July 20, 1999 and is headquartered in Jecheon-si, South Korea.

Korea Prime Pharmaceutical Co. Ltd. is a private company headquartered in the South Korea. The firm engages in pharmaceutical research and preparation activities. It was founded in 1995.

Tokyo Tanabe Co. Ltd., a subsidiary of Cegedim SA, is a Japanese company located in Tokyo. The firm produces and sells medicines.

Nitto Denko Corp. engages in the manufacture and sale of adhesives, optical films, semiconductors, electronic devices, and consumer products. It operates through the following segments: Industrial Tape, Optronics, Human Life, and Others. The Industrial Tape segment deals with the manufacture and sale of sealing, protective, process, and automotive materials. The Optronics segment offers optical films, printed circuits, and high-precision substrates. The Human Life segment handles the manufacturing services for nucleic acids, nucleic acid synthesis materials, and medical-related materials. The Others segment includes new businesses. The company was founded on October 25, 1918 and is headquartered in Osaka, Japan.

Eisai R&D Management Co., Ltd., a subsidiary of Eisai Co., Ltd., is a company headquartered in Bunkyo, Japan. The firm engages in research and development of pharmaceuticals.

Abbott Healthcare Products BV, part of Abbott Laboratories, is a company headquartered in Weesp, the Netherlands, that manufactures and distributes pharmaceuticals.

Harvest (Hunan) Pharmaceutical Technology Co., Ltd., established on 2011-12-15, Business scope includes medical research and experimental development;tablet,hard capsule,Granules,syrup,oral solution(Contains Chinese herbal extracts)production and sales;Chemical raw materials,Manufacture of chemical preparations;Chemicals,Chinese patent medicine,Chinese Herbal Medicine,Cosmetics and hygiene products,Chemical raw materials,Health products,disinfectant,Sanitation products,Medical Laboratory Equipment and Appliances,Sales of Chinese herbal medicines;Wholesale of chemical raw materials;medicine,Biological product,Healthy food,Health products,cosmetic,Chinese medicine,Plant extracts,R&D of Class II medical devices;Chemical product research and development,retail,Testing service;Biotechnology Development Services,transfer service;standard material,Class I medical device,Class II medical device,Retailing of Class III Medical Devices;Standard material development;Medical Laboratory Technology,Development of medical device technology;Technical research and development of pharmaceutical excipients,consult,technology transfer;Medical laboratory technical service;Medical device technology transfer service;Science and Technology Information Consulting Services;medical information,Technical Advisory Services;Class I medical device,Class II medical device,Production of Class III Medical Devices;Self-operated and agent import and export of various commodities and technologies,Except for the goods and technologies that the state restricts the company to operate or prohibits the import and export of.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Do not engage in unauthorizedP2Ponline loan,Equity crowdfunding,internet insurance,Asset management and cross-border finance,Third party payment,virtual currency transaction,ICO,Internet financial services such as illegal foreign exchange)

Qianhui Pharmaceutical (Anhui) Co., Ltd., established on 2006-10-18, Business scope includes pharmaceutical intermediates,API(loxoprofen sodium,Celecoxib,Eperisone Hydrochloride)research and development,production and sales;Self-operation and agency of various commodities and technology import and export business(Except for commodities and technologies that are restricted by the state to be operated by enterprises or prohibited from import and export).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)